Our Story
Center Laboratories (Center Ventures)
I. Global Investment Profile
-
Legal Entity Name: Center Laboratories, Inc. (TWSE: 4123).
-
Operating Brand: Center Ventures.
-
GICS Classification: Health Care (Sector 35) | Biotechnology (Sub-Industry 35201010).
-
Investability Benchmark: Maintains a Foreign Inclusion Factor (FIF) of ~0.525 and an Annualized Traded Value Ratio (ATVR) exceeding 20%, ensuring high accessibility for global passive and active funds.
II. Our Journey: From Pharmaceutical Leader to Biotech Industrial Bank
Established in 1959, Center Laboratories, Inc. (hereafter referred to as the "Company") was founded as a pharmaceutical company specializing in full-dosage drug development and manufacturing.
Phase 1: Market Dominance (1998–2007)
In 1998, the Company underwent its first reformation, repositioning itself as a professional oral liquid pharmaceutical leader. Over the next decade, we achieved a remarkable 70% market share in the domestic oral liquid drugs market. Recognizing the limits of local market saturation, we proactively sought new growth engines.
Phase 2: The "Biotech Industrial Bank" (2008–2018)
In 2008, the Company initiated its second business restructuring, shifting focus to a "Dual Growth Engine" strategy. While continuing to expand our oral liquid business, we repositioned ourselves as a “Biotechnology Industrial Bank.” Through subsidiaries like Bioengine Capital Inc. and Bioengine Technology Development Inc., we began strategic investments and incubation within the biotechnology sector.
Phase 3: Evolution into Center Ventures (2018–Present)
To maximize synergies across our expanding portfolio, the Company initiated its third transformation, evolving into the “Professional Biotechnology Venture Holdings Group” (also known as the “Center Ventures Group”).
Operating under the brand Center Ventures, we have become one of the leading professional biotechnology incubator platforms in the Asia-Pacific. We do not just invest; we revamp target operations, create value through Mergers and Acquisitions (M&A), and integrate resources to foster the next generation of industry leaders.
III. Strategic Vision & The Unicorn Goal
Today, Center Laboratories (Center Ventures) targets the incubation of "Unicorn" scale companies with market capitalizations exceeding NTD 30 billion each. We continue to seek potential opportunities in emergent industries—such as CDMOs and ADCs—that serve as secondary growth engines within our ecosystem.
By maintaining a high standard of transparency and meeting global liquidity indicators, we provide international institutional investors with a specialized gateway to the thriving Asia-Pacific biotech landscape.
-
1959-1998
Initial Stage
Established in 1959, the Center Laboratories, Inc. founded as a pharmaceutical company specializing in full-dosage drug development and manufacturing. In 1995, the capital size was NTD$40 million. -
1998-2007
Market Dominance
In 1998, the company experienced its first reformed and repositioned itself as a professional oral liquid pharmaceutical company specializing in diverse liquid drugs development and manufacturing and offering wide range of liquid drug solutions for medication purpose. -
2008-2018
Biotech Industrial Bank
To achieve business breakthrough with limited market share upside, the Company reformed its business structure and shifted it business strategies focuses on dual growth engines emphasis on strategic and organic growths.
‧Organic Growth – the Company continues to develop specialty drugs for combination therapy, and further penetrated into new fields product developments such as psychological and CNS (the central nervous system).
‧Strategic Growth– Post second reformed, the Center Laboratories repositioned itself as “Biotechnology Industrial Bank” and established Bioengine capital inc., and the Bioengine Technology Development Inc. The Company target to become one of the leading professional biotechnology investment company and incubator in Asia Pacific. -
2018-Now
Evolution into Center Ventures
Following the investment businesses expansion post second reformed, the Center Ventures Group initiated the third reformed that redefined the dual growth engines that shifted business strategies emphasis as the followings:
‧Organic Growth– The group targets to incubate more unicorn companies with market cap exceeding NTD$ 30 billion each, while aiming to assist target investment companies with the intention of revamping target investment company’s operations, with consolidation through Merger and Acquisition or re-selling at a profit.
‧Strategic Growth– Continues to seek for any potential opportunities in emergent industries that can serve as the second growth engines within the group.
Center Ventures Group’s Two Major Types of Investments:Core Business Investment & Emergent Industries Investment
-
Our Vision
We help the visionaries of tomorrow better the lives of today.
-
Our Mission
We bring together resources and experiences in Asia Pacific to help potential biotechnology and healthcare companies tap into the global market.
-
Corporate Value
Center Ventures Group corporate values include “Innovation, Integrity, Professionalism, Common Goods.” We believe that encouraging innovation to embracing possibilities and let impossible made possible. “Integrity” is the root of the life care, while integrity and transparency are our building blocks of our foundation. More importantly, we hope our “Professionalism” and resources can continue to make positive impact to our industry with “Common Goods” that brings better heath to human development and to achieve our vision on “helping the visionaries of tomorrow better the lives of today.”
